JPRN-UMIN000006490RecruitingPhase 2
A phase II study of subcutaneous injection of bortezomib in combination with oral cyclophosphamide and dexamethasone (sVCD) for relapsed or refractory multiple myeloma - subcutaneous injection of bortezomib, oral cyclophosphamide and dexamethasone (sVCD) therapy for myeloma
Kyushu Hematology Organization for Treatment (KHOT)0 sites31 target enrollmentStarted: October 20, 2011Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 31
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1.History of allergic reactions to compounds containing mannitol, bortezomib, or boron. 2.Poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to study protocol. 3.Active infection requiring treatment 4.Active hepatitis B or C. 5.Under treatment for a cancer other than multiple myeloma 6.Impaired kidney function requiring dialysis, liver function, cardiac function or pulmonary function. 7.Non-secretory myeloma, plasmacytoma, plasma cell leukemia, and POEMS syndrome. 8.Peripheral neuropathy > grade 2 9.Pregnant, lactation or potential
Investigators
Similar Trials
Active, not recruiting
Phase 1
Treatment with daratumumab injections in moderate to severe ME/CFSMyalgic Encephalomyelitis/Chronic Fatigue SyndromeMedDRA version: 20.1Level: LLTClassification code 10028414Term: Myalgic encephalomyelitisSystem Organ Class: 100000004862EUCTR2022-000281-18-NOHaukeland University Hospital, Dept. of Oncology and Medical Physics10
Active, not recruiting
Phase 1
Daratumumab in ME/CFSMyalgic Encephalomyelitis/Chronic Fatigue SyndromeMedDRA version: 26.1Level: LLTClassification code: 10028414Term: Myalgic encephalomyelitis Class: 10021881CTIS2024-512500-19-00Helse Bergen HF10
Completed
Phase 2
Phase II study of induction therapy with subcutaneous bortezomib, oral melphalan and predonisone for newly diagnosed multiple myeloma patients ineligible for stem cell transplantatioMultiple MyelomaJPRN-UMIN000010401Kanagawa Clinical Oncology Group37
Active, not recruiting
Phase 1
The effect of subcutaneous injection of Botulinum Toxin A on chronic wound pain in lower extremities, a prospective exploratory studychronic wound pain and wound healingMedDRA version: 20.1Level: LLTClassification code 10049542Term: Wound painSystem Organ Class: 100000004863EUCTR2021-000096-36-DKDepartment of Dermatology and Copenhagen Wound Healing Center, Bispebjerg Hospital16
Recruiting
Not Applicable
A phase II trial of the efficacy and safety of boring biopsy with rapid on-site evaluation for histological diagnosis of gastric mesenchymal tumorGastric mesenchymal tumorJPRN-UMIN000045414Osaka International Cancer Institute22